En bloc nephrectomy in patients undergoing post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous testis cancer

Indications, implications and outcomes

Peter A. Nash, Ilan Leibovitch, Richard Foster, Richard Bihrle, Randall G. Rowland, John P. Donohue

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Purpose: We review the indications for nephrectomy at post-chemotherapy retroperitoneal lymph node dissection, identify patients at risk for nephrectomy and assess the impact of nephrectomy on outcome. Materials and Methods: Using a computerized data base and chart review we retrospectively reviewed the records of 848 patients who underwent retroperitoneal lymph node dissection after chemotherapy. Results: En bloc nephrectomy was performed at retroperitoneal lymph node dissection after chemotherapy in 162 of the 848 patients (19%). The indications for nephrectomy included contiguous involvement of perirenal structures in 73% of the cases, renal vein thrombosis in 6%, a poorly functioning or nonfunctioning renal unit in 5% and a combination of these conditions in 16%. Pathological studies of the hilum revealed cancer in 20% of the cases, teratoma in 49% and fibrosis in 31%. Patients requiring nephrectomy had significantly more advanced disease and larger disease volume at presentation and after chemotherapy. There were no significant differences in perioperative morbidity or mortality compared with patients who did not undergo nephrectomy. Only 3 patients required perioperative dialysis and none required long-term renal support. Conclusions: These findings support en bloc nephrectomy at post-chemotherapy retroperitoneal lymph node dissection in select patients with large volume perihilar retroperitoneal disease.

Original languageEnglish
Pages (from-to)707-710
Number of pages4
JournalJournal of Urology
Volume159
Issue number3
DOIs
StatePublished - Mar 1998

Fingerprint

Testicular Neoplasms
Lymph Node Excision
Nephrectomy
Drug Therapy
Kidney
Renal Veins
Teratoma
Dialysis
Thrombosis
Fibrosis
Databases
Morbidity
Mortality

Keywords

  • Kidney
  • Lymph nodes
  • Nephrectomy
  • Testis

ASJC Scopus subject areas

  • Urology

Cite this

En bloc nephrectomy in patients undergoing post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous testis cancer : Indications, implications and outcomes. / Nash, Peter A.; Leibovitch, Ilan; Foster, Richard; Bihrle, Richard; Rowland, Randall G.; Donohue, John P.

In: Journal of Urology, Vol. 159, No. 3, 03.1998, p. 707-710.

Research output: Contribution to journalArticle

@article{3c6f5230a9f449e08a13b034c35a9620,
title = "En bloc nephrectomy in patients undergoing post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous testis cancer: Indications, implications and outcomes",
abstract = "Purpose: We review the indications for nephrectomy at post-chemotherapy retroperitoneal lymph node dissection, identify patients at risk for nephrectomy and assess the impact of nephrectomy on outcome. Materials and Methods: Using a computerized data base and chart review we retrospectively reviewed the records of 848 patients who underwent retroperitoneal lymph node dissection after chemotherapy. Results: En bloc nephrectomy was performed at retroperitoneal lymph node dissection after chemotherapy in 162 of the 848 patients (19{\%}). The indications for nephrectomy included contiguous involvement of perirenal structures in 73{\%} of the cases, renal vein thrombosis in 6{\%}, a poorly functioning or nonfunctioning renal unit in 5{\%} and a combination of these conditions in 16{\%}. Pathological studies of the hilum revealed cancer in 20{\%} of the cases, teratoma in 49{\%} and fibrosis in 31{\%}. Patients requiring nephrectomy had significantly more advanced disease and larger disease volume at presentation and after chemotherapy. There were no significant differences in perioperative morbidity or mortality compared with patients who did not undergo nephrectomy. Only 3 patients required perioperative dialysis and none required long-term renal support. Conclusions: These findings support en bloc nephrectomy at post-chemotherapy retroperitoneal lymph node dissection in select patients with large volume perihilar retroperitoneal disease.",
keywords = "Kidney, Lymph nodes, Nephrectomy, Testis",
author = "Nash, {Peter A.} and Ilan Leibovitch and Richard Foster and Richard Bihrle and Rowland, {Randall G.} and Donohue, {John P.}",
year = "1998",
month = "3",
doi = "10.1016/S0022-5347(01)63706-6",
language = "English",
volume = "159",
pages = "707--710",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - En bloc nephrectomy in patients undergoing post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous testis cancer

T2 - Indications, implications and outcomes

AU - Nash, Peter A.

AU - Leibovitch, Ilan

AU - Foster, Richard

AU - Bihrle, Richard

AU - Rowland, Randall G.

AU - Donohue, John P.

PY - 1998/3

Y1 - 1998/3

N2 - Purpose: We review the indications for nephrectomy at post-chemotherapy retroperitoneal lymph node dissection, identify patients at risk for nephrectomy and assess the impact of nephrectomy on outcome. Materials and Methods: Using a computerized data base and chart review we retrospectively reviewed the records of 848 patients who underwent retroperitoneal lymph node dissection after chemotherapy. Results: En bloc nephrectomy was performed at retroperitoneal lymph node dissection after chemotherapy in 162 of the 848 patients (19%). The indications for nephrectomy included contiguous involvement of perirenal structures in 73% of the cases, renal vein thrombosis in 6%, a poorly functioning or nonfunctioning renal unit in 5% and a combination of these conditions in 16%. Pathological studies of the hilum revealed cancer in 20% of the cases, teratoma in 49% and fibrosis in 31%. Patients requiring nephrectomy had significantly more advanced disease and larger disease volume at presentation and after chemotherapy. There were no significant differences in perioperative morbidity or mortality compared with patients who did not undergo nephrectomy. Only 3 patients required perioperative dialysis and none required long-term renal support. Conclusions: These findings support en bloc nephrectomy at post-chemotherapy retroperitoneal lymph node dissection in select patients with large volume perihilar retroperitoneal disease.

AB - Purpose: We review the indications for nephrectomy at post-chemotherapy retroperitoneal lymph node dissection, identify patients at risk for nephrectomy and assess the impact of nephrectomy on outcome. Materials and Methods: Using a computerized data base and chart review we retrospectively reviewed the records of 848 patients who underwent retroperitoneal lymph node dissection after chemotherapy. Results: En bloc nephrectomy was performed at retroperitoneal lymph node dissection after chemotherapy in 162 of the 848 patients (19%). The indications for nephrectomy included contiguous involvement of perirenal structures in 73% of the cases, renal vein thrombosis in 6%, a poorly functioning or nonfunctioning renal unit in 5% and a combination of these conditions in 16%. Pathological studies of the hilum revealed cancer in 20% of the cases, teratoma in 49% and fibrosis in 31%. Patients requiring nephrectomy had significantly more advanced disease and larger disease volume at presentation and after chemotherapy. There were no significant differences in perioperative morbidity or mortality compared with patients who did not undergo nephrectomy. Only 3 patients required perioperative dialysis and none required long-term renal support. Conclusions: These findings support en bloc nephrectomy at post-chemotherapy retroperitoneal lymph node dissection in select patients with large volume perihilar retroperitoneal disease.

KW - Kidney

KW - Lymph nodes

KW - Nephrectomy

KW - Testis

UR - http://www.scopus.com/inward/record.url?scp=0031930978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031930978&partnerID=8YFLogxK

U2 - 10.1016/S0022-5347(01)63706-6

DO - 10.1016/S0022-5347(01)63706-6

M3 - Article

VL - 159

SP - 707

EP - 710

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 3

ER -